

PATIENT ORGANISATION and PARLIAMENTARIAN COMMUNICATION
9 January 2024

**NHS Framework Agreement for Human Albumin and Normal and Anti-D
Immunoglobulin (commencing 1st April 2025)**

Dear [PATIENT ASSOCIATION LEAD/MP]

I am writing to you following the recent announcement of outcome of the Framework agreement and to provide additional insights from the CSL Behring perspective.

Suppliers of immunoglobulin and albumin products were invited to submit an application to the Human Albumin and Normal and Anti-D immunoglobulin framework that will commence on April 1, 2025. A Framework agreement is an arrangement between the NHS and one or more suppliers which establishes the terms, such as price and quantity, under which the NHS will buy products for an agreed time period. The Human Albumin and Normal and Anti-D Immunoglobulin Framework featured 6 segments; 5% intravenous immunoglobulin (IVIg), 10% IVIg, subcutaneous immunoglobulin (SCIg), anti-D immunoglobulin, facilitated subcutaneous immunoglobulin and albumin. CSL Behring submitted applications to supply the 10% IVIg, SCIg, Anti D immunoglobulin and albumin segments with Privigen, Hizentra, Rhophylac and Alburex, respectively.

CSL Behring was awarded Reserve Supplier status within the 10% IVIg and SCIg segments of the Framework, received a share award in the albumin segment and named the sole supplier in the anti-D immunoglobulin segment.

We understand that there may be questions relating to this outcome, specifically with regard to possible impact on patients and their clinicians. As a trusted partner to the NHS, we wanted to provide reassurance that we are here to stay. We are committed to continue to supply Privigen (Human normal immunoglobulin, 10% liquid) and Hizentra (Human normal immunoglobulin (SCIg) in both vials and pre-filled syringes to our UK patients and clinical teams wherever it is needed. We are working collaboratively with the MPSC to ensure that this is possible.

Summary

- CSL Behring participated in the tender process for the 2025 Human Albumin and Normal and Anti-D Immunoglobulin Framework. As part of the comprehensive submission process that covered a number of criteria, we were pleased to be able to offer a reduction in price to the NHS for both Hizentra and Privigen
- CSL Behring was assigned Reserve Supplier status for the supply of IVIg and SCIg
- CSL Behring has a strong heritage in immunoglobulin supply and is proud to put patients first. The relationships we have developed with Healthcare Professionals have established our reputation as a trusted partner for the NHS, we will continue to stay true to these values.
- We are working in partnership with the MPSC (Medicines Procurement and Supply Chain) to facilitate a safe and effective implementation of the new Framework. Regular reviews will take

place between CSL Behring and NHS England to plan and project the required volumes of both Privigen and Hizentra to ensure continued supplies to patients for as long as they are required.

- To support the transition, the MPSC has extended the existing Framework to run in parallel with the new Framework until at least September 2025 for IVIg, and at least December 2025 for SCIg. This provides continued access to Privigen and Hizentra for those patients with a clinical requirement, through the existing Framework mechanisms.
- Beyond December 2025, Privigen and Hizentra will continue to be available under the terms of the new Framework for patients for whom it is considered clinically relevant.

Frequently Asked Questions:

Q: Is CSL Behring leaving the UK IG market?

A: No. We remain committed to serving the needs of our patients and Healthcare Professionals within the UK. We will meet regularly with the MPSC to project and fulfil the defined volumes required of Privigen and Hizentra. CSL Behring and NHS Stakeholders appreciate that, where appropriate, patients may remain on their current product for clinical reasons, and we are committed to continuing to meet that requirement beyond the transition and throughout the Framework period.

Q: What was the Framework process and who was involved in the decision-making process?

A: The Framework process was led by the MPSC (Medicines Procurement and Supply Chain), and suppliers were invited to provide submissions in line with specific criteria. Decision-making software was then used to review supplier submissions and calculate the optimum overall Framework cost for the NHS.

Q: What does this mean for patients?

A: We understand that the MPSC will provide guidance on this in due course. Patient safety is the priority, and we understand that clinicians and their patients will be given an appropriate period of time to assess whether switching would be clinically appropriate, and carefully plan the transition to avoid any potential negative impact on the patient or local services.

Q. What if a patient cannot be switched onto a different product for clinical reasons?

A. Where a Hizentra or Privigen patient is unable to be treated with an alternative product awarded share on the Framework, they will be assessed and may be deemed suitable for maintenance on their current treatment. We are committed to supporting the NHS with the necessary volume to ensure a safe and effective implementation for such patients, monthly meetings between CSL Behring and the NHS will take place to predict the volumes required to do so.

Q: Why wasn't CSL Behring named as a preferred supplier?

A: CSL Behring carefully analysed the Global and European immunoglobulin market to produce an offering that reflected economic and surety of supply factors and was pleased to be able to provide a reduction in price for both Hizentra and Privigen to the NHS. CSL Behring remains confident that the submission made to the Framework represented a strong proposition based on the comprehensive analysis performed. We must assume that the submissions from other suppliers scored more favourably against the assessment criteria however, we are unable to comment on their methodology.

Q: What is a Reserve Supplier?

A: A Reserve Supplier does not have an assigned volume or confirmed share in the Framework agreement. However, NHS customers can purchase from this supplier to fulfil a defined clinical need or to address a shortfall in supply from one of the awarded suppliers.

Company contact

If you have any questions relating to this document or the Framework tender that you feel we can help with please feel free to reach out to me.

All medical enquiries should be directed to Medinfo@cslbehring.com

Joe Wildy

Director, Policy, Advocacy and Government Affairs

CSL Behring

4 Milton Road, Haywards Heath, RH16 1AH

mobile +44 7990 050460

CSL

Driven by Our Promise